Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy

Cannon, Christopher P., Steinberg, Benjamin A., Murphy, Sabina A., Mega, Jessica L., Braunwald, Eugene·2006·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2006.04.070

Cited by (772)

Items 101–200 of 772

  1. 2017 Taiwan lipid guidelines for high risk patients
    Yi‐Heng Li, Kwo‐Chang Ueng, Jiann‐Shing Jeng, Min‐Ji Charng, Tsung‐Hsien Lin, Kuo‐Liong Chien, Chih‐Yuan Wang, Ting‐Hsing Chao, Ping‐Yen Liu, Cheng‐Huang Su et al. · 2017 · Journal of the Formosan Medical Association
  2. Cardio-Ankle Vascular Index is a New Noninvasive Parameter of Arterial Stiffness
    Akira Takaki, Hiroshi Ogawa, Takatoshi Wakeyama, Takahiro Iwami, Masayasu Kimura, Yasuyuki Hadano, Susumu Matsuda, Yousuke Miyazaki, Tomoko Matsuda, Atsushi Hiratsuka et al. · 2007 · Circulation Journal
  3. Exercise-based Cardiac Rehabilitation in Patients With Coronary Heart Disease: meta-analysis Outcomes Revisited
    Neil Oldridge · 2012 · Future Cardiology
  4. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients
    Edward J. Mills, Chris O’Regan, Oghenowede Eyawo, Ping Wu, Fergal P. Mills, Otavio B Berwanger, Matthias Briel · 2011 · European Heart Journal
  5. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention
    Glenn N. Levine, Eric Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg et al. · 2011 · Catheterization and Cardiovascular Interventions
  6. Statins as Regulators of Redox State in the Vascular Endothelium: Beyond Lipid Lowering
    Marios Margaritis, Keith M. Channon, Charalambos A. Antoniades · 2013 · Antioxidants and Redox Signaling
  7. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
    Jonathan Afilalo, Agnieska A Majdan, Mark Jeffrey Eisenberg · 2007 · Heart
  8. SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
    Abstr Act · 2008
  9. INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
    Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova, Galina Afanas'evna Mel'nichenko, Natalya Valentinovna Mazurina, Elena Nikolaevna Andreeva, I. Z. Bondarenko, Гусова Залина Руслановна, F. K. Dzgoeva, М. С. Елисеев, Ekaterina Vladimirovna Ershova et al. · 2021 · Obesity and metabolism
  10. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia
    Gliozzi, Micaela, Walker, Ross, Muscoli, Saverio, Vitale, Cristiana, Gratteri, Santo, Carresi, Cristina, Musolino, Vincenzo, Russo, Vanessa, Janda, Elzbieta, Ragusa, Salvatore et al. · 2013 · International Journal of Cardiology
  11. Update on Dyslipidemia
    Abhimanyu Garg, Vinaya Simha · 2007 · The Journal of Clinical Endocrinology & Metabolism
  12. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
    T. N. Patel, Mehdi H. Shishehbor, Deepak L. Bhatt · 2007 · European Heart Journal
  13. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Alexander Tenenbaum, Enrique Z. Fisman · 2012 · Cardiovascular Diabetology
  14. Benefit of Early Statin Therapy in Patients With Acute Myocardial Infarction Who Have Extremely Low Low-Density Lipoprotein Cholesterol
    Ki Hong Lee, Myung Ho Jeong, Ha Mi Kim, Youngkeun Ahn, Jong‐Hyun Kim, Shung Chull Chae, Young Jo Kim, Seung‐Ho Hur, In Whan Seong, Taek Jong Hong et al. · 2011 · Journal of the American College of Cardiology
  15. Relationship between cardiac rehabilitation and survival after acute cardiac hospitalization within a universal health care system
    David Andrew Alter, PAUL I. OH, Alice S. Chong · 2009 · European Journal of Cardiovascular Prevention & Rehabilitation
  16. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary
    Glenn N. Levine, Eric Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg et al. · 2011 · Journal of the American College of Cardiology
  17. Statin Therapy and Saphenous Vein Graft Disease After Coronary Bypass Surgery: Analysis From the CASCADE Randomized Trial
    Alexander Kulik, Pierre Voisine, Patrick Mathieu, Roy G. Masters, Thierry G. Mesana, Michel R. Le May, Marc Ruel · 2011 · The Annals of Thoracic Surgery
  18. New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
    Nick S. Nurmohamed, Ann Marie Návar, John J.P. Kastelein · 2021 · Journal of the American College of Cardiology
  19. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): Characteristics of a randomized trial among 12 064 myocardial infarction survivors
    SEARCH Study Collaborative Group · 2007 · American Heart Journal
  20. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease
    Sabina A. Murphy, Terje Rolf Pedersen, Zbigniew A. Gaciong, R Češka, Ежов Марат Владиславович, Derek Leslie Connolly, J. Wouter Jukema, Kálmán Tóth, Matti J. Tikkanen, Kyungah Im et al. · 2019 · JAMA Cardiology
  21. Dyslipidemia in women: etiology and management
    Peter Paul Toth, Binh An P. Phan · 2014 · International Journal of Women s Health
  22. Vulnerable Plaque: Definition, Diagnosis, and Treatment
    Pedro Moreno · 2009 · Cardiology Clinics
  23. Statin use and musculoskeletal pain among adults with and without arthritis
    Buettner, Catherine, Rippberger, Matthew J., Smith, Julie K., Leveille, Suzanne G., Davis, Roger B., Mittleman, Murray A. · 2012 · The American Journal of Medicine
  24. Statin Use and Risk of Delirium in the Critically Ill
    Valerie Joan Page, Daniel H J Davis, Xiao Bei Zhao, Sam Norton, Annalisa Casarin, Thomas Brown, Eugene Wesley Ely, Daniel Francis McAuley · 2014 · American Journal of Respiratory and Critical Care Medicine
  25. Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia
    Michael S. Kostapanos, Haralampos J. Milionis, Moses Elisaf · 2010 · American Journal of Cardiovascular Drugs
  26. Lifestyle Approaches and Dietary Strategies to Lower LDL-Cholesterol and Triglycerides and Raise HDL-Cholesterol
    Heather Ilene Katcher, Alison Marie Hill, Julie Lg Lanford, Janey S. Yoo, Penny M. Kris‐Etherton · 2009 · Endocrinology and Metabolism Clinics of North America
  27. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis
    Peter Paul Toth · 2012 · Yearbook of Medicine
  28. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
    Michael A. Blazing, Robert Patrick Giugliano, Christopher Paul Cannon, Thomas A. Musliner, Andrew M. Tershakovec, Jennifer A. White, Craig Reist, Amy McCagg, Eugene Braunwald M. D, Robert M. Califf · 2014 · American Heart Journal
  29. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary
    L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter et al. · 2011 · Journal of the American College of Cardiology
  30. Cardiovascular risk prevention and all-cause mortality in primary care patients with an abdominal aortic aneurysm
    Sandeep Singh Bahia, Alberto Vidal‐Diez, Sreenivasa Rao Kondapally Seshasai, Ilya Shpitser, Jack R W Brownrigg, Benjamin Oliver Patterson, Kausik Kumar Ray, Peter Holt, MATT M. THOMPSON, Alan Karthikesalingam · 2016 · British journal of surgery
  31. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy
    Lei Zhang, Yan Liu, Xiao Ting Lu, Yi Ling Wu, Cheng Zhang, Xiao Ping Ji, Rong Wang, Chun Xi Liu, Jin Bo Feng, Hong Jiang et al. · 2009 · American Journal of Physiology-Heart and Circulatory Physiology
  32. Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia
    Robin Haring, Sebastian Edgar Baumeister, Henry Völzke, Marcus Dörr, Stephan Burkhard Felix, Heyo K. Kroemer, Matthias A. Nauck, Henri Wallaschofski · 2010 · European Journal of Cardiovascular Prevention & Rehabilitation
  33. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care
    Valeria Guglielmi, Alfonso Bellia, Serena Pecchioli, David Della‐Morte, Damiano Parretti, Iacopo Cricelli, Gerardo Medea, Paolo Sbraccia, Davide Lauro, Claudio Alberto Cricelli et al. · 2017 · Atherosclerosis
  34. Safety and efficacy of ezetimibe: A meta-analysis
    Savarese, Gianluigi, De Ferrari, Gaetano M., Rosano, Giuseppe M.C., Perrone-Filardi, Pasquale · 2015 · International Journal of Cardiology
  35. An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design
    Robert M. Califf, Yuliya V. Lokhnygina, Christopher Paul Cannon, Michael E. Stepanavage, Carolyn H. McCabe, Thomas A. Musliner, Richard C. Pasternak, Michael A. Blazing, Robert Patrick Giugliano, Robert A. Harrington et al. · 2010 · American Heart Journal
  36. Inhibition of Macrophage Phagocytotic Activity by a Receptor-targeted Polymer Vesicle-based Drug Delivery Formulation of Pravastatin
    Pavel Brož, Nadav Ben-Haim, Mariusz Grzelakowski, Stephan C. U. Marsch, Wolfgang Peter Meier, Patrick Hunziker · 2008 · Journal of Cardiovascular Pharmacology
  37. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)
    Murphy, Sabina A., Cannon, Christopher P., Wiviott, Stephen D., de Lemos, James A., Blazing, Michael A., McCabe, Carolyn H., Califf, Robert M., Braunwald, Eugene · 2007 · The American Journal of Cardiology
  38. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence
    D. Preiss, N. Sattar · 2009 · Clinical Endocrinology
  39. Atorvastatin
    Andrea Poli · 2007 · Drugs
  40. Noninvasive Assessment of Endothelial Function in Clinical Practice
    Antonio Luis Arrebola-Moreno, Martín Laclaustra, Juan Carlos Kaski · 2011 · Revista Española de Cardiología (English Edition)
  41. Statins: an essential component in the management of carotid artery disease
    Paraskevas, Kosmas I., Hamilton, George, Mikhailidis, Dimitri P. · 2007 · Journal of Vascular Surgery
  42. Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta‐Analysis of 20 Randomized Controlled Trials
    Chuanwei Li, Ling Lin, Wen Zhang, Liang Zhou, Hongyong Wang, Xiaoli Luo, Hao Luo, Yue Cai, Chunyu Zeng · 2015 · Journal of the American Heart Association
  43. Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety
    Alexander Kulik, Marc Ruel · 2009 · Expert Opinion on Drug Safety
  44. Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering
    Pedersen, Terje R. · 2010 · American Journal Cardiovascular Drugs
  45. Prevalence of dyslipidemia and its associated factors among Jordanian adults
    Yousef Saleh Khader, Anwar M Batieha, Mohammed S. El-Khateeb, Mousa Al Omari, Kamel M. Ajlouni · 2009 · Journal of clinical lipidology
  46. Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
    Heart Protection Study Collaborative Group · 2009 · Circulation Cardiovascular Quality and Outcomes
  47. Effect of statin therapy on the progression of coronary atherosclerosis
    Jinwei Tian, Xia Gu, Yanli Sun, Xiang Ban, Yun Xiao, Sining Hu, Bo Yu · 2012 · BMC Cardiovascular Disorders
  48. Blood pressure control and cardiovascular risk reduction.
    G Antonakoudis, Leonidas E. Poulimenos, Konstantinos Kifnidis, C Zouras, H. Antonakoudis · 2007 · PubMed Central
  49. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study
    Michel Farnier, Maurizio Rocco Averna, Luc H. Missault, H Vaverková, Margus Viigimaa, Rachid Massaad, K. Vandormael, Amy O. Johnson‐Levonas, Philippe Brudi · 2009 · International Journal of Clinical Practice
  50. Benefit of Intensive Statin Therapy in Women
    Quynh A. Truong, Sabina A. Murphy, Carolyn H. McCabe, Annemarie M. Armani, Christopher Paul Cannon · 2011 · Circulation Cardiovascular Quality and Outcomes
  51. Low-density lipoprotein cholesterol lowering treatment: the current approach
    Irina Crîşmaru, Anca Pantea Stoian, Ovidiu Gabriel Bratu, Mihnea‐Alexandru Găman, Ana Maria Alexandra Stănescu, Nicolae Bacalbaşa, Camelia Cristina Diaconu · 2020 · Lipids in Health and Disease
  52. Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy
    Roberto R. Giraldez, Robert Patrick Giugliano, Satishkumar Mohanavelu, Sabina A. Murphy, Carolyn H. McCabe, Christopher Paul Cannon, Eugene Braunwald M. D · 2008 · Journal of the American College of Cardiology
  53. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe
    Jean Ferrières, Gaetano Maria De Ferrari, Michel Paul Hermans, Moses Elisaf, Peter Paul Toth, Martin Horack, Philippe Brudi, Dominik Lautsch, Lori D. Bash, Carl A. Baxter et al. · 2018 · European Journal of Preventive Cardiology
  54. Effects of Maximal Atorvastatin and Rosuvastatin Treatment on Markers of Glucose Homeostasis and Inflammation
    Nuntakorn Thongtang, Masumi Ai, Seiko Otokozawa, Thomas V. Himbergen, Bela F. Asztalos, Katsuyuki Nakajima, Evan A. Stein, Peter H. Jones, Ernst J. Schaefer · 2011 · The American Journal of Cardiology
  55. Dyslipidemia in primary care – prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)
    Elisabeth Steinhagen‐Thiessen, Peter Bramlage, Christian Lösch, Hans Hauner, Heribert Schunkert, Anja Vogt, Jürgen Wasem, Karl‐Heinz Jöckel, Susanne Moebus · 2008 · Cardiovascular Diabetology
  56. Advances in nanotechnology for the management of coronary artery disease
    June‐Wha Rhee, Joseph C. Wu · 2012 · Trends in Cardiovascular Medicine
  57. Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival
    Nicholas James Leeper, Reza Ardehali, Emil M. deGoma, Paul A. Heidenreich · 2007 · Circulation
  58. The Therapeutic Role of Niacin in Dyslipidemia Management
    William E. Boden, Mandeep S. Sidhu, Peter Paul Toth · 2013 · Journal of Cardiovascular Pharmacology and Therapeutics
  59. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis
    P.P. Toth · 2012 · Yearbook of Endocrinology
  60. Future of Cholesteryl Ester Transfer Protein Inhibitors
    Rader, Daniel J., deGoma, Emil M. · 2014 · Annual Review of Medicine
  61. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials
    Doris T. Chan, Ashley Bruce Irish, Gursharan K. Dogra, Gerald Francis Watts · 2007 · Atherosclerosis
  62. Atorvastatin Reduces Macrophage Accumulation in Atherosclerotic Plaques
    Massimo Puato, Elisabetta Faggin, Marcello Rattazzi, Alberto Zambon, Francesco Cipollone, Franco Grego, Lorenzo Ganassin, Mario Plebani, Andrea Mezzetti, Paolo Pauletto · 2010 · Stroke
  63. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
    Michel Farnier · 2008 · Vascular Health and Risk Management
  64. Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke
    Georgios K. Tsivgoulis, Apostolοs Safouris, Dong‐Eog Kim, Andrei V. Alexandrov · 2018 · Journal of Stroke
  65. Rho‐GTPase and Atherosclerosis: Pleiotropic Effects of Statins
    Anping Cai, Yingling Zhou, Liwen Li · 2015 · Journal of the American Heart Association
  66. Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases
    Tao Li, Weitao Liang, Xijun Xiao, Yongjun Qian · 2018 · International Journal of Nanomedicine
  67. HDL-c is a powerful lipid predictor of cardiovascular diseases
    Éric Bruckert, Boris Hansel · 2007 · International Journal of Clinical Practice
  68. Effects of Maximal Doses of Atorvastatin Versus Rosuvastatin on Small Dense Low-Density Lipoprotein Cholesterol Levels
    Masumi Ai, Seiko Otokozawa, Bela F. Asztalos, Katsuyuki Nakajima, Evan A. Stein, Peter H. Jones, Ernst J. Schaefer · 2007 · The American Journal of Cardiology
  69. Nanoplumbers: biomaterials to fight cardiovascular diseases
    Flavio Dormont, Mariana Varna, Patrick Couvreur · 2017 · Materials Today
  70. Association of statin use with Parkinson's disease: Dose–response relationship
    Su‐Min Jeong, Wooyoung Jang, Dong Wook Shin · 2019 · Movement Disorders
  71. Evaluación no invasiva de la función endotelial en la práctica clínica
    Antonio Luis Arrebola-Moreno, Martín Laclaustra, Juan Carlos Kaski · 2011 · Revista Española de Cardiología
  72. Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3R,5R)-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of Hypercholesterolemia
    Jeffrey A. Pfefferkorn, Chulho Choi, Scott D. Larsen, Bruce J. Auerbach, R. H. Hutchings, William Park, Valerie Askew, Lisa Dillon, Jeffrey Christian Hanselman, Zhiwu Lin et al. · 2007 · Journal of Medicinal Chemistry
  73. Bundesärztekammer Kassenärztliche Bundesvereinigung Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
    Nationale VersorgungsLeitlinie · 2011
  74. Optimization of caseinate-coated simvastatin-zein nanoparticles: improved bioavailability and modified release characteristics
    Osama A. A. Ahmed, Khaled M. Hosny, Majid Mohammad Al-Sawahli, Usama Ahmed Fahmy · 2015 · Drug Design Development and Therapy
  75. Combination therapy of statins and fibrates in the management of cardiovascular risk
    Catherine Fiévet, Bart Staels · 2009 · Current Opinion in Lipidology
  76. Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant
    Bonaventure Yiu Ming Ip, Kui Kai Lau, Ho Ko, Lucas Lau, Alan Yao, Grace Lai‐Hung Wong, Terry Cheuk‐Fung Yip, Xinyi Leng, Howard H.W. Chan, Helen Chan et al. · 2023 · Neurology
  77. Promise of Low-Density Lipoprotein–Lowering Therapy for Primary and Secondary Prevention
    Scott M. Grundy · 2008 · Circulation
  78. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary
    Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel E. Dagogo-Jack, Michael Davidson, DANIEL F. EINHORN, Jeffrey R. Garber et al. · 2015 · Endocrine Practice
  79. Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.
    N. John Bosomworth · 2013 · Europe PMC (PubMed Central)
  80. RETRACTED: Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial
    Roeland Huijgen, S. Matthijs Boekholdt, Benoît J. Arsenault, Weihang Bao, Jean‐Michel Davaine, Fatiha Tabet, Francine Petrides, Kerry‐Anne Rye, David A. DeMicco, Philip J. Barter et al. · 2012 · Journal of the American College of Cardiology · Retracted
  81. Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort Study
    Julien Bezin, Nicholas D Moore, Yohann Mansiaux, Philippe Gabríel Steg, Antoine Pariente · 2019 · The American Journal of Medicine
  82. Roadmap Consensus on Carotid Artery Plaque Imaging and Impact on Therapy Strategies and Guidelines: An International, Multispecialty, Expert Review and Position Statement
    Luca Saba, Waleed Brinjikji, John David Spence, Max Wintermark, Maurício Castillo, Gert Jan de Borst, Qi Yang, Chun Yuan, Andrew J. Buckler, Myriam Edjlali et al. · 2021 · American Journal of Neuroradiology
  83. Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease
    Mark Y. Chan, Kenneth W. Mahaffey, Lena J. Sun, Karen S. Pieper, Harvey Douglas White, Philip E. Aylward, James J. Ferguson, Robert M. Califf, Matthew T. Roe · 2008 · JACC: Cardiovascular Interventions
  84. Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment
    Anping Cai, Liwen Li, Ying Zhang, Yujin Mo, Weiyi Mai, Yingling Zhou · 2013 · Disease Markers
  85. Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis
    Xiaoxin Li, Hongzhao Qi, Weigang Cui, Zhibin Wang, Xiuxiu Fu, Tianxiang Li, Huibo Ma, Yanyan Yang, Tao Yu · 2022 · Molecular Therapy
  86. Dyslipidaemia in the Middle East: Current status and a call for action
    Khalid Al‐Rasadi, Wael A. Almahmeed, Khalid F. AlHabib, Marianne Abifadel, Hasan Ali Farhan, Saud N. Alsifri, S Jambart, Mohammad Zubaid, Zuhier Ahmed Awan, Khalid Al-Waili et al. · 2016 · Atherosclerosis
  87. Human genetics as a foundation for innovative drug development
    Alexander Kamb, Sean Harper, Kāri Stefánsson · 2013 · Nature Biotechnology
  88. Low-Density Lipoprotein Cholesterol Reduction: The End Is More Important Than the Means
    John C. LaRosa · 2007 · The American Journal of Cardiology
  89. Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study)
    Franklin Joseph Zieve, NANETTE KASS WENGER, Ori Ben‐Yehuda, Christian M Constance, Steven R. Bird, Raymond Lee, Mary Elizabeth Hanson, Charlotte Jones-Burton, Andrew M. Tershakovec · 2009 · The American Journal of Cardiology
  90. Ameliorative effects of Nigella sativa on dyslipidemia
    Sedigheh Asgary, Amirhossein Sahebkar, Najmeh Goli‐malekabadi · 2015 · Journal of Endocrinological Investigation
  91. Drug Treatment of Hyperlipidaemia
    Peter Paul Toth · 2010 · Drugs
  92. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients
    John Munkhaugen, Elise Sverre, Jan Erik Otterstad, Kari Peersen, Erik Gjertsen, Joep Perk, Lars Lysgaard Gullestad, Torbjørn Moum, Toril Dammen, Einar Husebye · 2017 · European Journal of Preventive Cardiology
  93. Niacin: The Evidence, Clinical Use, and Future Directions
    Todd C. Villines, Andrew S. Kim, Rosco Steven Gore, Allen J. Taylor · 2011 · Current Atherosclerosis Reports
  94. Lipid control in patients with diabetes mellitus
    D. J. Betteridge · 2011 · Nature Reviews Cardiology
  95. Long-Term Benefit of Statin Therapy Initiated??during Hospitalization for??an??Acute??Coronary Syndrome
    Anthony A. Bavry, Girish R. Mood, Dharam J. Kumbhani, Peter Borek, Arman T. Askari, Deepak L. Bhatt · 2007 · American Journal of Cardiovascular Drugs
  96. Anti-PCSK9 therapies for the treatment of hypercholesterolemia
    Amanda J. Hooper, John R. Burnett · 2012 · Expert Opinion on Biological Therapy
  97. Six-month survival benefits associated with clinical guideline recommendations in acute coronary syndromes
    Derek P. Chew, Frederick A. Anderson, Álvaro Avezum, Kim Allen Eagle, Gordon FitzGerald, Joel M. Gore, Rebecca Dedrick, David B. Brieger, for the GRACE Investigators · 2010 · Heart
  98. Triglyceride and cardiovascular risk: A critical appraisal
    Awadhesh Kumar Singh, Ritu Singh · 2016 · Indian Journal of Endocrinology and Metabolism
  99. Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II
    Kian Keong Poh, Baishali M. Ambegaonkar, Carl A. Baxter, Philippe Brudi, Wacin Buddhari, Fu‐Tien Chiang, Martin Horack, Yangsoo Jang, Brett Johnson, Dominik Lautsch et al. · 2018 · European Journal of Preventive Cardiology
  100. PCSK9 inhibitors and cardiovascular outcomes
    Daniel Steffens, Peter Bramlage, Céline Scheeff, Mario Kašner, Adel Hassanein, Julian Friebel, Ursula Rauch‐Kröhnert · 2019 · Expert Opinion on Biological Therapy